The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Guillermo A. Herrera - One of the best experts on this subject based on the ideXlab platform.
-
light chain mediated acute tubular Interstitial Nephritis a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia
Archives of Pathology & Laboratory Medicine, 2009Co-Authors: Xin Gu, Guillermo A. HerreraAbstract:Abstract Context.—Acute renal failure may be the first clinical presentation in patients with plasma cell dyscrasia. Recognition of the unusual Interstitial inflammatory lesion associated with monoclonal light chains and renal failure described herein is important to guide clinicians in requesting appropriate tests to confirm plasma cell dyscrasia and providing adequate treatment. Objective.—To describe an unusual pattern of tubular Interstitial Nephritis in patients with underlying plasma cell dyscrasia characterized by an Interstitial inflammatory reaction associated with deposition of light chains along tubular basement membranes. Design.—Eight cases of light-chain–mediated acute tubular Interstitial Nephritis were identified from the archives of 4296 kidney biopsy specimens. In all cases, routine light microscopic examination, direct immunofluorescence, and electron microscopic examination were performed. Ultrastructural immunogold labeling was performed in specimens with inconclusive findings and in ...
-
light chain mediated acute tubular Interstitial Nephritis a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia
Archives of Pathology & Laboratory Medicine, 2009Co-Authors: Xin Gu, Guillermo A. HerreraAbstract:Abstract Context.—Acute renal failure may be the first clinical presentation in patients with plasma cell dyscrasia. Recognition of the unusual Interstitial inflammatory lesion associated with monoclonal light chains and renal failure described herein is important to guide clinicians in requesting appropriate tests to confirm plasma cell dyscrasia and providing adequate treatment. Objective.—To describe an unusual pattern of tubular Interstitial Nephritis in patients with underlying plasma cell dyscrasia characterized by an Interstitial inflammatory reaction associated with deposition of light chains along tubular basement membranes. Design.—Eight cases of light-chain–mediated acute tubular Interstitial Nephritis were identified from the archives of 4296 kidney biopsy specimens. In all cases, routine light microscopic examination, direct immunofluorescence, and electron microscopic examination were performed. Ultrastructural immunogold labeling was performed in specimens with inconclusive findings and in ...
Xin Gu - One of the best experts on this subject based on the ideXlab platform.
-
light chain mediated acute tubular Interstitial Nephritis a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia
Archives of Pathology & Laboratory Medicine, 2009Co-Authors: Xin Gu, Guillermo A. HerreraAbstract:Abstract Context.—Acute renal failure may be the first clinical presentation in patients with plasma cell dyscrasia. Recognition of the unusual Interstitial inflammatory lesion associated with monoclonal light chains and renal failure described herein is important to guide clinicians in requesting appropriate tests to confirm plasma cell dyscrasia and providing adequate treatment. Objective.—To describe an unusual pattern of tubular Interstitial Nephritis in patients with underlying plasma cell dyscrasia characterized by an Interstitial inflammatory reaction associated with deposition of light chains along tubular basement membranes. Design.—Eight cases of light-chain–mediated acute tubular Interstitial Nephritis were identified from the archives of 4296 kidney biopsy specimens. In all cases, routine light microscopic examination, direct immunofluorescence, and electron microscopic examination were performed. Ultrastructural immunogold labeling was performed in specimens with inconclusive findings and in ...
-
light chain mediated acute tubular Interstitial Nephritis a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia
Archives of Pathology & Laboratory Medicine, 2009Co-Authors: Xin Gu, Guillermo A. HerreraAbstract:Abstract Context.—Acute renal failure may be the first clinical presentation in patients with plasma cell dyscrasia. Recognition of the unusual Interstitial inflammatory lesion associated with monoclonal light chains and renal failure described herein is important to guide clinicians in requesting appropriate tests to confirm plasma cell dyscrasia and providing adequate treatment. Objective.—To describe an unusual pattern of tubular Interstitial Nephritis in patients with underlying plasma cell dyscrasia characterized by an Interstitial inflammatory reaction associated with deposition of light chains along tubular basement membranes. Design.—Eight cases of light-chain–mediated acute tubular Interstitial Nephritis were identified from the archives of 4296 kidney biopsy specimens. In all cases, routine light microscopic examination, direct immunofluorescence, and electron microscopic examination were performed. Ultrastructural immunogold labeling was performed in specimens with inconclusive findings and in ...
Jose Lutzky - One of the best experts on this subject based on the ideXlab platform.
-
Interstitial Nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
Journal for ImmunoTherapy of Cancer, 2017Co-Authors: Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka, Jose LutzkyAbstract:Background Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory diseases. Case presentation We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute Interstitial Nephritis during immune checkpoint therapy. We emphasize the causal association between immune checkpoint inhibitors and the Nephritis. The timing of drug administration and appearance of Nephritis is suggestive of a causal relation between the checkpoint inhibitor therapy and this adverse event. Conclusions Although uncommon, some side effects from checkpoint inhibitors can be severe and may need to be addressed with immunosuppression. Given the increasing frequency of immunotherapy use, awareness should be raised in regards to immune side effects and their appropriate management.
-
Interstitial Nephritis in melanoma patients secondary to pd 1 checkpoint inhibitor
Journal for ImmunoTherapy of Cancer, 2017Co-Authors: Julia Escandon, Stephanie Peacock, Asaad Trabolsi, David B. Thomas, Ayman Layka, Jose LutzkyAbstract:Immune checkpoint inhibitors have become the first line therapy in melanoma treatment and their use is extending to other malignancies. However, we are still learning about immune side effects produced by these drugs and their severity especially in patients with history of inflammatory diseases. We present two cases of metastatic melanoma treated with nivolumab and pembrolizumab (anti PD-1). Both patients developed acute Interstitial Nephritis during immune checkpoint therapy. We emphasize the causal association between immune checkpoint inhibitors and the Nephritis. The timing of drug administration and appearance of Nephritis is suggestive of a causal relation between the checkpoint inhibitor therapy and this adverse event. Although uncommon, some side effects from checkpoint inhibitors can be severe and may need to be addressed with immunosuppression. Given the increasing frequency of immunotherapy use, awareness should be raised in regards to immune side effects and their appropriate management.
Dieter Haffner - One of the best experts on this subject based on the ideXlab platform.
-
isolated sarcoid granulomatous Interstitial Nephritis responding to infliximab therapy
American Journal of Kidney Diseases, 2005Co-Authors: Julia Thumfart, Dominik N Muller, Birgit Rudolph, Miriam Zimmering, Uwe Querfeld, Dieter HaffnerAbstract:Sarcoidosis is a systemic disease with multiorgan involvement. In children, renal impairment of sarcoidosis usually is caused by either hypercalcemia leading to nephrocalcinosis or Interstitial Nephritis with or without granulomata. We report the case of a 13-year-old boy presenting with severe arterial hypertension and acute renal failure caused by an isolated sarcoid granulomatous Interstitial Nephritis (GIN). Other known causes of GIN, eg, drug intake or fungal or mycobacterial infection, were excluded, and there was no evidence of extrarenal sarcoid involvement. Renal function improved initially with prednisone treatment. Blood pressure was controlled using ramipril, nifedipine, furosemide, dihydralazine, and metoprolol. Later, the patient showed signs of severe steroid toxicity and progressive renal failure. Monthly treatment with infliximab, a tumor necrosis factor-α antibody, was started, resulting in steady improvement in renal function and resolution of renal granulomata. In addition, antihypertensive medication could be reduced, and low-dose prednisone therapy was maintained. To our knowledge, this is the first report of successful treatment with infliximab of a patient with sarcoid GIN.
Simon D Roger - One of the best experts on this subject based on the ideXlab platform.
-
proton pump inhibitors and acute Interstitial Nephritis
Clinical Gastroenterology and Hepatology, 2006Co-Authors: Nimeshan Geevasinga, Patrick L Coleman, Angela C Webster, Simon D RogerAbstract:Background & Aims: Proton pump inhibitors (PPIs) are a widely prescribed class of drugs, and their usage worldwide is increasing. Although well-tolerated, there have been case reports and a recent case series implicating these drugs in acute Interstitial Nephritis (AIN) and progression to acute renal failure (ARF). The aim of this study was to investigate how widespread this complication is in Australia, to identify which PPIs are implicated, and to establish whether PPI-induced AIN is a class effect. Methods: We undertook a retrospective case review of potential cases at 2 teaching hospitals and a review of registry data from the Therapeutic Goods Administration of Australia (TGA). Parameters sought included the drug implicated, concurrent medications, symptoms, signs, serum creatinine, and time of onset after prescription. Results: We identified 18 cases of biopsy-proven PPI-induced AIN causing ARF in the retrospective case review, which is the largest hospital-based case series to date. The TGA registry data identified an additional 31 cases of "biopsy proven Interstitial Nephritis." An additional 10 cases of "suspected Interstitial Nephritis," 20 cases of "unclassified acute renal failure," and 26 cases of "renal impairment" were also identified. All 5 commercially available PPIs were implicated in these cases. Conclusion: With the ever more widespread use of this class of medications, PPI-induced AIN is likely to become more frequent. There is now evidence to incriminate all the commercially available PPIs, suggesting there is a class effect. Failure to recognize this entity might have catastrophic long-term consequences including chronic kidney disease. Increased awareness might facilitate more rapid diagnosis and management of this potentially reversible condition.
-
rabeprazole induced acute Interstitial Nephritis
Nephrology, 2005Co-Authors: Nimeshan Geevasinga, Patrick L Coleman, Simon D RogerAbstract:Acute Interstitial Nephritis is an uncommon but important cause of acute renal failure. Proton pump inhibitors are now thought to be the most common class of drugs implicated in drug-induced acute Interstitial Nephritis. This is the first reported case of rabeprazole-induced acute Interstitial Nephritis.
